arsenic has been researched along with Hematologic Malignancies in 31 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 22 (70.97) | 29.6817 |
| 2010's | 7 (22.58) | 24.3611 |
| 2020's | 2 (6.45) | 2.80 |
| Authors | Studies |
|---|---|
| Bunce, CM; Drayson, MT; Khanim, FL | 1 |
| Al Ustwani, O; Griffiths, EA; Torka, P; Wang, ES; Wetzler, M | 1 |
| Falchi, L; Kantarjian, HM; Ravandi-Kashani, F; Verstovsek, S | 1 |
| Colombo, M; Diaz, Z; Komarnitsky, PB; Kourelis, M; Mann, KK; Marcoux, S; Miller, WH | 1 |
| Chan, GC; Sze, DM | 1 |
| Gotlib, J; Oh, ST | 1 |
| Fan, LP; Fu, HY; Shen, JZ; Shen, SF; Wu, Y; Zhou, HR | 1 |
| Hu, XM; Liu, F; Ma, R | 1 |
| Takahashi, S | 1 |
| Shen, Q; Tang, YH | 1 |
| Han, ZC; Liu, P | 1 |
| Dutcher, JP; Garl, S; Lucariello, R; Unnikrishnan, D; Varshneya, N; Wiernik, PH | 1 |
| Evens, AM; Gartenhaus, RB; Tallman, MS | 1 |
| Estrov, Z; Verstovsek, S | 1 |
| Kwong, YL | 1 |
| Sekeres, MA | 1 |
| Douer, D; Tallman, MS | 1 |
| Amadori, S; Fenaux, P; Ludwig, H; O'dwyer, M; Sanz, M | 1 |
| Boehrer, S; Chow, KU; Hoelzer, D; Mitrou, PS; Nowak, D | 1 |
| Beran, M; Freireich, E; Giles, F; Kantarjian, H; Perez, N; Quintás-Cardama, A; Ravandi-Kashani, F; Verstovsek, S | 1 |
| Bonati, A; Lunghi, P; Rizzoli, V | 1 |
| Augustyniak, C; Evens, AM; Gordon, LI; Gupta, R; Mehta, J; Ziegler, SL | 1 |
| Au, WY; Fong, BM; Kwong, YL; Tam, S; Wan, TS; Yip, SF | 1 |
| Novick, SC; Warrell, RP | 1 |
| Murgo, AJ | 1 |
| Tallman, MS | 1 |
| Chen, G; Huang, Y; Zhu, Q | 1 |
| Bloomfield, CD; Slack, JL; Tallman, MS; Tricot, G; Waxman, S | 1 |
| Miller, WH; Waxman, S | 1 |
| Cheng, YY; Guo, HR; Li, CY; Lin, MH | 1 |
| Bandopadhyay, D; Chakraborty, T; Chaudhuri, U; De, M; Halder, A; Paul, S | 1 |
20 review(s) available for arsenic and Hematologic Malignancies
| Article | Year |
|---|---|
Does the pursuit of scientific excellence serve or hamper translational medical research: an historical perspective from hematological malignancies.
Topics: Arsenic Trioxide; Arsenicals; Hematologic Neoplasms; Humans; Leukemia, Promyelocytic, Acute; Oxides; Thalidomide; Translational Research, Biomedical; Tretinoin | 2022 |
Swallowing a bitter pill-oral arsenic trioxide for acute promyelocytic leukemia.
Topics: Administration, Intravenous; Administration, Oral; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Arsenic Trioxide; Arsenicals; Hematologic Neoplasms; Humans; Leukemia, Promyelocytic, Acute; Oxides; Remission Induction; Treatment Outcome | 2016 |
The evolution of arsenic in the treatment of acute promyelocytic leukemia and other myeloid neoplasms: Moving toward an effective oral, outpatient therapy.
Topics: Administration, Oral; Ambulatory Care; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Arsenic Trioxide; Arsenicals; Clinical Trials, Phase III as Topic; Female; Follow-Up Studies; Forecasting; Hematologic Neoplasms; Humans; Infusions, Intravenous; Leukemia, Promyelocytic, Acute; Male; Oxides; Randomized Controlled Trials as Topic; Risk Assessment; Treatment Outcome | 2016 |
Supplements for immune enhancement in hematologic malignancies.
Topics: Adult; Animals; Antineoplastic Agents; Arsenic Trioxide; Arsenicals; beta-Glucans; Child; Clinical Trials as Topic; Dietary Supplements; Digestive System Neoplasms; Drug Screening Assays, Antitumor; Drug Synergism; Drugs, Chinese Herbal; Ganoderma; Hematologic Neoplasms; Herb-Drug Interactions; Humans; Immunologic Factors; Mice; Oxides; Phytotherapy; Plant Preparations; Polyporus; Thalidomide | 2009 |
Combination therapy with arsenic trioxide for hematological malignancies.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Arsenic Trioxide; Arsenicals; Cell Line, Tumor; Hematologic Neoplasms; Humans; Oxides | 2010 |
[Molecular mechanism of malignant hematological tumor cell apoptosis induction by active components of traditional Chinese herbs].
Topics: Apoptosis; Arsenic Trioxide; Arsenicals; Diterpenes; Drugs, Chinese Herbal; Epoxy Compounds; Hematologic Neoplasms; Humans; Oxides; Phenanthrenes; Quercetin; Tumor Cells, Cultured | 2010 |
Treatment of acute promyelocytic leukemia and other hematologic malignancies with arsenic trioxide: review of clinical and basic studies.
Topics: Antineoplastic Agents; Arsenic Trioxide; Arsenicals; Hematologic Neoplasms; Humans; Leukemia, Promyelocytic, Acute; Oxides | 2003 |
The potential of arsenic trioxide in the treatment of malignant disease: past, present, and future.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Arsenic Trioxide; Arsenicals; Hematologic Neoplasms; Humans; Oxidation-Reduction; Oxides | 2004 |
Arsenic derivatives as therapeutic agents for hematologic malignancies.
Topics: Administration, Oral; Antineoplastic Agents; Arsenicals; Hematologic Neoplasms; Humans | 2004 |
Arsenic trioxide in the treatment of haematological malignancies.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Arsenic Trioxide; Arsenicals; Clinical Trials as Topic; Drug Resistance, Neoplasm; Hematologic Neoplasms; Humans; Oxides; Remission Induction; Salvage Therapy; Tretinoin | 2004 |
Arsenic trioxide as a treatment for myelodysplastic syndrome.
Topics: Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Arsenic Trioxide; Arsenicals; Ascorbic Acid; Cell Division; Clinical Trials as Topic; Dexamethasone; DNA-Binding Proteins; Drug Therapy, Combination; Glutathione; Hematologic Neoplasms; Humans; Leukemia, Promyelocytic, Acute; MDS1 and EVI1 Complex Locus Protein; Multicenter Studies as Topic; Myelodysplastic Syndromes; Neovascularization, Pathologic; Oxides; Proto-Oncogenes; Transcription Factors | 2005 |
Arsenic trioxide: new clinical experience with an old medication in hematologic malignancies.
Topics: Antineoplastic Agents; Arsenic Trioxide; Arsenicals; Clinical Trials as Topic; Hematologic Neoplasms; Humans; Oxides | 2005 |
Use of arsenic trioxide in haematological malignancies: insight into the clinical development of a novel agent.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Arsenic Trioxide; Arsenicals; Clinical Trials as Topic; Drug Design; Hematologic Neoplasms; Humans; Mitochondria; Oxides; Polymerase Chain Reaction; Prognosis | 2005 |
Novel agents aiming at specific molecular targets increase chemosensitivity and overcome chemoresistance in hematopoietic malignancies.
Topics: Animals; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Agents; Apoptosis; Arsenic Trioxide; Arsenicals; Benzamides; Drug Resistance, Neoplasm; Enzyme Inhibitors; Hematologic Neoplasms; Histone Deacetylase Inhibitors; Humans; Imatinib Mesylate; Oligonucleotides, Antisense; Oxides; Piperazines; Proteasome Endopeptidase Complex; Pyrimidines; Rituximab; Thalidomide | 2006 |
Arsenic derivatives in hematologic malignancies: a role beyond acute promyelocytic leukemia?
Topics: Administration, Oral; Antineoplastic Agents; Arsenic Trioxide; Arsenicals; Disease-Free Survival; Hematologic Neoplasms; Humans; Leukemia, Promyelocytic, Acute; Oxides; Remission Induction; Treatment Outcome | 2006 |
Arsenic trioxide in hematological malignancies: the new discovery of an ancient drug.
Topics: Antineoplastic Agents; Arsenic Trioxide; Arsenicals; Clinical Trials as Topic; Hematologic Neoplasms; Humans; Multiple Myeloma; Oxides; Practice Patterns, Physicians'; Treatment Outcome | 2006 |
Arsenicals in hematologic cancers.
Topics: Animals; Antineoplastic Agents; Apoptosis; Arsenic Trioxide; Arsenicals; Clinical Trials as Topic; Drug Evaluation, Preclinical; Hematologic Neoplasms; Humans; Leukemia, Promyelocytic, Acute; Oxides; Tumor Cells, Cultured | 2000 |
Clinical trials of arsenic trioxide in hematologic and solid tumors: overview of the National Cancer Institute Cooperative Research and Development Studies.
Topics: Antineoplastic Agents; Arsenic Trioxide; Arsenicals; Clinical Trials as Topic; Hematologic Neoplasms; Humans; National Institutes of Health (U.S.); Oxides; United States | 2001 |
Arsenic trioxide: its role in acute promyelocytic leukemia and potential in other hematologic malignancies.
Topics: Animals; Antineoplastic Agents; Arsenic Trioxide; Arsenicals; Hematologic Neoplasms; Humans; Leukemia, Promyelocytic, Acute; Oxides; Survival Analysis | 2001 |
Advances in the management of acute promyelocytic leukemia and other hematologic malignancies with arsenic trioxide.
Topics: Antineoplastic Agents; Arsenic Trioxide; Arsenicals; Clinical Trials as Topic; Hematologic Neoplasms; Humans; Leukemia, Promyelocytic, Acute; Multiple Myeloma; Myelodysplastic Syndromes; Oxides; Recurrence; Remission Induction; Survival Analysis; Treatment Outcome; Tretinoin | 2002 |
1 trial(s) available for arsenic and Hematologic Malignancies
| Article | Year |
|---|---|
Cardiac monitoring of patients receiving arsenic trioxide therapy.
Topics: Adult; Aged; Antineoplastic Agents; Arrhythmias, Cardiac; Arsenic Trioxide; Arsenicals; Edema; Electrocardiography, Ambulatory; Female; Hematologic Neoplasms; Humans; Male; Middle Aged; Oxides; Prospective Studies | 2004 |
10 other study(ies) available for arsenic and Hematologic Malignancies
| Article | Year |
|---|---|
A novel arsenical has antitumor activity toward As2O3-resistant and MRP1/ABCC1-overexpressing cell lines.
Topics: Animals; Anthracenes; Antineoplastic Agents; Apoptosis; Arsenic Trioxide; Arsenicals; Cell Line, Tumor; Drug Resistance, Neoplasm; Glutathione; Hematologic Neoplasms; Humans; JNK Mitogen-Activated Protein Kinases; MAP Kinase Kinase 4; Mice; Multidrug Resistance-Associated Proteins; Oncogene Proteins, Fusion; Oxidative Stress; Oxides | 2008 |
Antiangiogenic therapy in myelodysplastic syndromes: is there a role?
Topics: Angiogenesis Inhibitors; Animals; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Arsenic Trioxide; Arsenicals; Bevacizumab; Clinical Trials as Topic; Drug Approval; Farnesyltranstransferase; Hematologic Neoplasms; Humans; Lenalidomide; Myelodysplastic Syndromes; Neovascularization, Pathologic; Oxides; Protein-Tyrosine Kinases; Thalidomide | 2008 |
Arsenic trioxide inhibits DNA methyltransferase and restores expression of methylation-silenced CDKN2B/CDKN2A genes in human hematologic malignant cells.
Topics: Antineoplastic Agents; Arsenic Trioxide; Arsenicals; Cyclin-Dependent Kinase Inhibitor p15; DNA Methylation; DNA Modification Methylases; Drug Evaluation, Preclinical; Enzyme Inhibitors; Gene Expression Regulation, Neoplastic; Gene Silencing; Genes, p16; Hematologic Neoplasms; Humans; Oxides; Promoter Regions, Genetic; Tumor Cells, Cultured; U937 Cells | 2010 |
Application and assessment of Chinese arsenic drugs in treating malignant hematopathy in China.
Topics: Arsenic Trioxide; Arsenicals; China; Drugs, Chinese Herbal; Hematologic Neoplasms; Humans; Oxides | 2010 |
Sustained hematologic and central nervous system remission with single-agent denileukin diftitox in refractory adult T-cell leukemia/lymphoma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Arsenic Trioxide; Arsenicals; Bone Marrow Transplantation; Central Nervous System Neoplasms; Diphtheria Toxin; Drug Resistance, Neoplasm; Hematologic Neoplasms; Humans; Interferons; Interleukin-2; Leukemia-Lymphoma, Adult T-Cell; Male; Middle Aged; Oxides; Recombinant Fusion Proteins; Recurrence; Remission Induction; Transplantation, Homologous; Zidovudine | 2007 |
Second hematological malignancies during arsenic trioxide therapy of B-cell lymphomas.
Topics: Aged; Arsenic Trioxide; Arsenicals; Female; Hematologic Neoplasms; Humans; Lymphoma, B-Cell; Male; Neoplasms, Second Primary; Oxides | 2009 |
[The relationship between sensitivity to arsenic trioxide and antioxidative capacity of malignant hematopoietic cells].
Topics: Apoptosis; Arsenic Trioxide; Arsenicals; Cell Survival; Glutathione Peroxidase; Glutathione Transferase; Hematologic Neoplasms; HL-60 Cells; Humans; K562 Cells; Oxides; Superoxide Dismutase; Tumor Cells, Cultured; U937 Cells | 2000 |
Differentiation induction as a treatment for hematologic malignancies.
Topics: Arsenic Trioxide; Arsenicals; Cell Differentiation; Hematologic Neoplasms; Leukemia, Promyelocytic, Acute; Models, Biological; Oncogene Proteins, Fusion; Oxides; Signal Transduction; Transcription, Genetic | 2002 |
Arsenic in Drinking Water and Incidences of Leukemia and Lymphoma: Implication for Its Dual Effects in Carcinogenicity.
Topics: Arsenic; Carcinogenesis; Drinking Water; Female; Hematologic Neoplasms; Humans; Incidence; Leukemia; Lymphoma; Male; Neoplasms | 2022 |
Association of genotoxic effects of arsenic with haematological malignancy in West Bengal.
Topics: Adolescent; Adult; Arsenic; Child; Chromosome Aberrations; Female; Hair; Hematologic Neoplasms; Humans; India; Male; Middle Aged; Mutagens; Nails; Retrospective Studies; Water Pollutants, Chemical; Young Adult | 2011 |